Phase III data support Novartis's US biosimilar filgrastim ambitions
This article was originally published in Scrip
Executive Summary
Novartis's Sandoz has shown in Phase III data that the company's biosimilar filgrastim is comparable to its licensed reference product, Amgen's blockbuster Neupogen, in the prevention of neutropenia in breast cancer patients. The pivotal data will support Novartis's US filing of the biosimilar product, which is thought to be the first to attempt access via the US's new biosimilar pathway.